Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data

Megan Othus, PhD, Guillermo Garcia-Manero, MD, John E. Godwin, MD, James K. Weick, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 291.

https://doi.org/10.1182/blood-2019-127356

Published: 2019

Journal Articles

2 nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

Megan Othus, PhD, Elihu H. Estey, MD, Guillermo Garcia-Manero, MD, Brent Wood, MD PhD, Derek Stirewalt, MD, John Godwin, MD, James K. Weick, MD, Jeanne E. Anderson, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Roland B. Walter, MD PhD MS

Blood (2018) 132 (Supplement 1): 3978.

https://doi.org/10.1182/blood-2018-99-117525

Published: 2018

Journal Articles

Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data

Megan Othus, PhD, Guillermo Garcia-Manero, MD, John Godwin, MD, James K. Weick, MD, Jeanne E. Anderson, MD, Derek Stirewalt, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD

Blood (2017) 130 (Supplement 1): 1301.

https://doi.org/10.1182/blood.V130.Suppl_1.1301.1301

Published: 2017

Journal Articles

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Thomas M Habermann, MD, Fangxin Hong, PhD, Vicki A. Morrison, MD, Shaker R. Dakhil, MD, James K. Weick, MD, Stanley R. Frankel, MD, Randy D. Gascoyne, MD, Richard I Fisher, MD, Bruce D. Cheson, MD, Edie A. Weller, PhD, Brad S. Kahl, M.D., Bruce A. Peterson, MD, Howard S Hochster, MD, Sandra J. Horning, M.D.

Blood (2012) 120 (21): 3705.

https://doi.org/10.1182/blood.V120.21.3705.3705

Published: 2012

Journal Articles

Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study

Jane N. Winter, MD, Fangxin Hong, PhD, Lisa M. Rimsza, MD, Michael LeBlanc, Ph.D., Daina Variakojis, M.D., Maryla Krajewska, M.D., Thomas M. Habermann, MD, Ari Melnick, MD, James K. Weick, MD, Frederick Pollock, Ihab Botros, Ph.D., John C. Reed, MD, PhD, Richard I Fisher, MD, Brad S. Kahl, MD, Sandra J. Horning, MD, Randy D. Gascoyne, MD

Blood (2011) 118 (21): 87.

https://doi.org/10.1182/blood.V118.21.87.87

Published: 2011

NARROW

Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data

2 nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study

Email alerts

ASH Publications

American Society of Hematology

Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data

2 nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only